The Radiation Oncology Market is growing at a fast pace as cancer cases rise and treatment tools get smarter. It was valued at US$ 8,924.44 million in 2023. It is projected to reach US$ 23,620.56 million by 2031. That works out to a CAGR of 13.0% from 2023 to 2031. Radiation oncology uses high-energy beams, such as X-rays and gamma rays, to destroy cancer cells. It is one of the fastest-developing cancer treatment methods. Better machines and wider awareness are bringing it to more patients each year.
What Is Driving the Market?
Rising cancer cases are the first driver. The World Health Organization reports 20 million new cases and 9.7 million deaths in 2022. New cases are expected to reach about 35 million by 2050. Lung, breast, colorectal, and prostate cancers lead the list. Radiation is often part of treatment, so demand keeps climbing.
Investment is the second driver. Governments and private groups are putting money into radiation therapy centers and wider cancer care. Better access and higher quality of care help more patients get treated sooner.
Get exclusive insights into the Radiation Oncology Market – https://www.theinsightpartners.com/sample/TIPRE00004195
Strategic moves by companies are the third driver. Firms keep launching products, winning approvals, forming partnerships, and completing deals. These steps push the field forward and open new paths for growth.
Every market has limits. Even so, the strong pull from patient need and new technology keeps the outlook positive.
Which Segment Leads?
By type, external beam radiation therapy led the market in 2023. It held a 61.2% share. Internal beam radiation therapy is expected to grow at a higher CAGR. Within the external beam group, 3D conformal radiotherapy is set to grow the fastest, at a CAGR of 13.3%. Within the internal beam group, brachytherapy held the largest share, at 72.9% in 2023.
By application, breast cancer held the largest share in 2023. It is also expected to grow the fastest, with a CAGR of 13.6%. The report also covers prostate, lung, head and neck, and cervical cancers. Each one calls for a different treatment plan, so the market offers many ways to grow.
Which Region Leads?
North America dominated the market. It held a 45.4% share in 2023. Rising cancer cases and advanced technology support that lead. The United States holds the main share in the region, and its market is projected to grow at a CAGR of 12.4%. Over 1 million US cancer patients received radiation therapy in 2022. About two-thirds of cancer patients worldwide are estimated to receive radiation as part of care.
Asia Pacific is expected to grow the fastest. Its CAGR is projected at 15.2%. Developing economies in the region offer wide room for growth. In India, about 1.39 million cancer cases were reported in 2020. The government is building cancer care infrastructure and running programs for prevention and screening. The report also covers Europe, the Middle East and Africa, and South and Central America.
Which Companies Are Prominent?
The report profiles these players:
- Varian Medical Systems Inc
- Elekta AB
- Accuray Incorporated
- IBA Worldwide (Ion Beam Applications SA)
- Becton Dickinson & Co
- Perspective Therapeutics Inc
- Nordion
- Mevion Medical Systems
- NTP Radioisotopes
- Mallinckrodt Plc
The list mixes makers of treatment machines with suppliers of radioisotopes. Some firms build linear accelerators and proton systems. Others supply the radioactive materials used in internal therapy. Together they cover the whole treatment chain.
Recent moves show where competition is heading. In May 2024, Elekta launched Evo, a CT linear accelerator with AI-enhanced imaging for adaptive radiation therapy. In February 2024, Varian received US FDA clearance and the CE mark for its Halcyon and Ethos systems with HyperSight imaging. In May 2024, IBA signed a contract for a Proteus ONE compact proton therapy system in Connecticut.
Buy the Full Report https://www.theinsightpartners.com/buy/TIPRE00004195
What Is Changing in 2026?
Technology is the biggest change. AI-enhanced imaging now lets teams adjust treatment while the patient is on the table. Elekta’s Evo and GE HealthCare’s Revolution RT, both launched in May 2024, aim to improve image accuracy and simplify planning. Better images mean more precise treatment and more personal care.
AI is also entering treatment planning. In September 2023, MVision AI launched a guideline-based tool for contouring, the step where teams outline tumors and healthy organs. Tools like this can save time and help clinicians refine their skills.
Compact systems are the third shift. Smaller proton therapy units, such as IBA’s Proteus ONE, can fit into more hospitals. That may bring advanced treatment to places that could not host larger machines. The report expects technological advances to drive the key trends in the years ahead.
What Are the Investment Opportunities?
The report puts the total addressable market for 2024 to 2031 at about US$ 99,766.43 million. That shows how much room is left for new products and new buyers.
Partnerships are one opening. In May 2024, the Icon Group teamed up with Cyberknife Australia Pty Ltd to set up as many as six new radiation oncology clinics. Joint ventures like this can spread advanced treatment faster.
Emerging economies are another. Governments in developing regions are building cancer care infrastructure. That should create demand for machines, software, and services.
Innovation is the third path. Companies that launch better imaging, smarter planning tools, and compact systems can win share. Radiopharmaceuticals add another route, as firms such as Curium pursue approvals for targeted radiation drugs.
Taken together, these paths point to strong, long-term growth through 2031.
About US: The Insight Partners is among the leading market research and consulting firms in the world. We take pride in delivering exclusive reports along with sophisticated strategic and tactical insights into the industry. Reports are generated through a combination of primary and secondary research, solely aimed at giving our clientele a knowledge-based insight into the market and domain. This is done to assist clients in making wiser business decisions. A holistic perspective in every study undertaken form an integral part of our research methodology and makes the report unique and reliable.
Contact US
If you have any queries about this report or if you would like further information, please contact us:
Phone: +1-646-491-9876
E-mail: sales@theinsightpartners.com
Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish
